1 Jun 2015 07:00
1 June 2015
Motif Bio Plc
("Motif" or the "Company")
Motif partners with Leading Global CRO for Phase III Clinical Trials with Iclaprim
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its wholly-owned subsidiary, Motif BioSciences Inc., has signed Letters of Intent (LOIs) and interim agreements with a leading global Clinical Research Organisation (CRO). Under the terms of these interim agreements, the CRO will undertake preparations for two Phase III, randomised, double-blind, multicenter clinical trials to evaluate the efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections ("ABSSSIs") suspected or confirmed to be due to Gram-positive pathogens.
Iclaprim is a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria. Motif is investing over US$950,000 under the terms of the interim agreements, to be paid by 31 July 2015. Pursuant to the LOIs, the parties will negotiate the terms and conditions of a mutually acceptable formal agreement for the conduct of the two studies.
The selected CRO is one of the world's top five providers of Phase I-IV clinical trial management services and to date, has contributed to the development of all of the top 50 prescription medicines on the market. The CRO has unique insights into infectious disease clinical trials with over 17,000 patients in more than 150 studies.
Graham Lumsden, CEO of Motif Bio plc, commented:
"Retaining this leading global CRO is the first major step for Motif in achieving our goal of successfully completing Phase III clinical trials with iclaprim. The safety and efficacy of this broad spectrum antibiotic has already been proven in many patients, and we believe that iclaprim may be an important treatment option for ABSSSIs. Combining the knowledge and experience of Motif's management and directors with the infectious diseases expertise of our selected CRO is expected to add tremendous value for our investors."
Enquiries
Motif Bio plc Graham Lumsden (Chief Executive Officer) Robert Bertoldi (Chief Financial Officer) www.motifbio.com
| info@motifbio.com |
MC Services AG (TRADE PR) Raimund Gabriel Shaun Brown
|
+49 (0) 89 210 2280 +44 (0) 207 148 5998 |
Cairn Financial Advisers LLP (NOMAD) | +44 (0) 20 7148 7900 |
Tony Rawlinson Carolyn Sansom
| |
Northland Capital Partners Limited (BROKER) | +44 (0) 20 7382 1100 |
Gerry Beaney/David Hignell John Howes/Mark Treharne (Broking)
| |
Plumtree Capital Limited (FINANCIAL ADVISOR) | +44 (0) 207 183 2493 |
Stephen Austin
| |
Yellow Jersey PR Limited (FINANCIAL PR) Dominic Barretto Fiona Walker
| +44 (0) 7768 537 739 |
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.